CS
CLDI icon

Clear Street’s Calidi Biotherapeutics CLDI Stock Holding History

Clear Street’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-112
Closed -$2.25M – 1151
2023
Q2 		$2.25M Buy
112
+111
+11,100% +$2.21M 0.02% 223
2023
Q1 		$11.2K Buy
+1
New +$19.6K ﹤0.01% 490
2022
Q4 		– Hold
0
– – – 921
2022
Q3 		– Hold
0
– – – 1033
2022
Q2 		– Hold
0
– – – 916

Other funds holding CLDI

MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $2.8B AUM 13.35% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SAMC
Spectrum Asset Management (California) Newport Beach, California $360M AUM 19.03% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $394M AUM 20.27% 1-Year Est. Return
DIM
Delta Investment Management San Francisco, California $608M AUM 25.3% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Clear Street's CLDI Position: Q3 2023 in Review

Clear Street sold out of Calidi Biotherapeutics (CLDI) in Q3 2023, closing a stake of 112 shares — an estimated $2.25M sold.

Clear Street first reported a position in CLDI in Q1 2023 and held it in 2 quarters. The position peaked at $2.25M in Q2 2023. 10 funds tracked by Wall St. Rank hold CLDI as of Q3 2023.

  • Clear Street reported no remaining Calidi Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Clear Street sold 112 Calidi Biotherapeutics shares in Q3 2023, an estimated $2.25M.
  • Clear Street first reported a position in Calidi Biotherapeutics in Q1 2023 and held it in 2 quarters.
  • Clear Street's Calidi Biotherapeutics position peaked at $2.25M in Q2 2023.
  • 10 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2023.

Based on Clear Street's 13F filing for Q3 2023, filed 13 Nov 2023.